Genetically engineered humanized anti-ganglioside GM2 antibody against multiple organ metastasis produced by GM2-expressing small-cell lung cancer cells. (Q39478999)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Genetically engineered humanized anti-ganglioside GM2 antibody against multiple organ metastasis produced by GM2-expressing small-cell lung cancer cells.	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21895875%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

Genetically engineered humanized anti-ganglioside GM2 antibody against multiple organ metastasis produced by GM2-expressing small-cell lung cancer cells (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21895875%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21895875%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21895875%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

9

object named as

Saburo Sone

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21895875%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

author name string

Hideaki Bando

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21895875%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

Shinji Takeuchi

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21895875%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

Kenji Kita

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21895875%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

Qi Li

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21895875%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

Shiro Akinaga

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21895875%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

Yasuhiko Nishioka

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21895875%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

Seiji Yano

10

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21895875%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

publication date

30 September 2011

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21895875%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21895875%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

102

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21895875%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

12

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21895875%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

2157-2163

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21895875%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

Prognosis of 6644 resected non-small cell lung cancers in Japan: a Japanese lung cancer registry study

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.02093.X

21 January 2018

A new international staging system for lung cancer

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.02093.X

21 January 2018

Epidemiology of lung cancer prognosis: quantity and quality of life

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.02093.X

21 January 2018

Regional lymph node classification for lung cancer staging

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.02093.X

21 January 2018

Studies of a ganglioside fraction extracted from human malignant melanoma

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.02093.X

21 January 2018

Ganglioside GM3:GD3 ratio as an index for the management of melanoma

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.02093.X

21 January 2018

Therapeutic efficacy of mouse-human chimeric anti-ganglioside GM2 monoclonal antibody against multiple organ micrometastases of human lung cancer in NK cell-depleted SCID mice

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.02093.X

21 January 2018

Anti-ganglioside GM2 monoclonal antibody-dependent killing of human lung cancer cells by lymphocytes and monocytes.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.02093.X

21 January 2018

Immunological circumvention of multiple organ metastases of multidrug resistant human small cell lung cancer cells by mouse-human chimeric anti-ganglioside GM2 antibody KM966.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.02093.X

21 January 2018

Panitumumab monotherapy in patients with metastatic colorectal cancer and cetuximab infusion reactions: a series of four case reports

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.02093.X

21 January 2018

Potelligent antibodies as next generation therapeutic antibodies

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.02093.X

21 January 2018

Selective long-term elimination of natural killer cells in vivo by an anti-interleukin 2 receptor beta chain monoclonal antibody in mice

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.02093.X

21 January 2018

Rapid colorimetric assay for cell viability: application to the quantitation of cytotoxic and growth inhibitory lymphokines.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.02093.X

21 January 2018

Engineered therapeutic antibodies with improved effector functions

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.02093.X

21 January 2018

The novel chimeric anti-NCAM (neural cell adhesion molecule) antibody ch.MK1 displays antitumor activity in SCID mice but does not activate complement-dependent cytolysis (CDC).

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.02093.X

21 January 2018

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q39478999&oldid=2107099179"